Halozyme Therapeutics, Inc.
US ˙ NasdaqGS ˙ US40637H1095

SecurityHALO / Halozyme Therapeutics, Inc.
InstitutionMackenzie Financial Corp
Latest Disclosed Ownership69,326 shares
Latest Disclosed Value $ 4,480,539
Mackenzie Financial Corp reports 20.31% increase in ownership of HALO / Halozyme Therapeutics, Inc.

On May 13, 2026 - Mackenzie Financial Corp filed a 13F-HR form disclosing ownership of 69,326 shares of Halozyme Therapeutics, Inc. (US:HALO) valued at $4,480,539 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 18, 2026 disclosing 57,623 shares of Halozyme Therapeutics, Inc.. This represents a change in shares of 20.31% during the quarter. The current value of the position is $4,958,889 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 69,326 11,703 20.31 4,481 15.08 0.0054
2026-02-18 2025-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 57,623 22,292 63.09 3,893 50.25 0.0046
2025-11-13 2025-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 35,331 -83,095 -70.17 2,591 -57.94 0.0031
2025-08-13 2025-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 118,426 32,817 38.33 6,161 12.78 0.0080
2025-05-07 2025-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 85,609 68,213 392.12 5,463 557.28 0.0078
2025-05-02 2024-12-31 13F/A-2 HALOZYME THERAPEUTICS COM 40637H109 17,396 -1,442 -7.65 832 -22.91 0.0011
2025-02-20 2024-12-31 13F/A-1 HALOZYME THERAPEUTICS COM 40637H109 17,396 -1,442 832 0.0011
2025-02-14 2024-12-31 13F Halozyme Therapeutics Common Stock 40637H109 17,396 -1,442 816 0.0012
2024-11-13 2024-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 18,838 4,059 27.46 1,078 39.46 0.0015
2024-08-14 2024-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 14,779 4,393 42.30 774 83.18 0.0011
2024-05-10 2024-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 10,386 163 1.59 423 11.94 0.0006
2024-01-30 2023-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 10,223 0 0.00 378 -1.82 0.0006
2023-10-25 2023-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 10,223 0 0.00 385 1.86 0.0006
2023-08-03 2023-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 10,223 -2,520 -19.78 377 -22.43 0.0006
2023-04-24 2023-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 12,743 -606 -4.54 487 -35.97 0.0008
2023-02-14 2022-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 13,349 1,987 17.49 760 69.04 0.0013
2022-10-07 2022-09-30 13F Halozyme Therapeutics Common Stock 40637H109 11,362 -50,894 -81.75 449 -83.61 0.0008
2022-08-10 2022-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 62,256 -14,604 -19.00 2,739 -10.64 0.0044
2022-05-13 2022-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 76,860 -3,719 -4.62 3,065 -5.40 0.0041
2022-02-14 2021-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 80,579 -510 -0.63 3,240 -1.79 0.0044
2021-11-08 2021-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 81,089 54,652 206.73 3,299 174.69 0.0047
2021-08-11 2021-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 26,437 4,770 22.02 1,201 33.00 0.0017
2021-05-14 2021-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 21,667 21,667 903 0.0014
2021-02-10 2020-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 0 -17,120 -100.00 0 -100.00
2020-11-13 2020-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 17,120 -10,822 -38.73 450 -39.92 0.0011
2020-08-13 2020-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 27,942 -14,076 -33.50 749 -0.93 0.0020
2020-05-14 2020-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 42,018 30,208 255.78 756 261.72 0.0024
2020-02-13 2019-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 11,810 11,810 209 0.0005
2019-11-14 2019-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 0 -16,820 -100.00 0 -100.00
2019-08-23 2019-06-30 13F/A-1 HALOZYME THERAPEUTICS COM 40637H109 16,820 0 0.00 289 6.64 0.0007
2019-08-14 2019-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 16,820 0 289
2019-05-15 2019-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 16,820 16,820 271 0.0007
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.